Cannabidiol in Adults With Lennox–Gastaut Syndrome: Real‐World Experience
Pyae Aung, Debbie Miller, Emily Sewell, Laura Mantoan Ritter, Evangelia Theochari, Ioannis Stavropoulos, Robert Delamont, Mark P. Richardson, Joel S. Winston, Lina Nashef · 2026
Read Cannabidiol in Adults With Lennox–Gastaut Syndrome: Real‐World Experience by Pyae Aung, Debbie Miller, Emily Sewell, Laura Mantoan Ritter, Evangelia Theochari, Ioannis Stavropoulos, Robert Delamont, Mark P. Richardson, Joel S. Winston, Lina Nashef (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13615429.txt.
Description
Pyae Aung leads a team reporting real-world results for cannabidiol, a cannabis-derived medicine, used as an add-on treatment in adults with Lennox-Gastaut syndrome, a severe epilepsy that begins in childhood. Their single centre reviewed records and carer seizure diaries for 79 adults, median age 29, followed for a median of 41 months. Four patients died of causes unrelated to the drug, and 86 percent were still taking it at last follow-up.
Across all seizure types, 59.5 percent of patients had at least half their seizures cut at six months, rising to 67.1 percent at last follow-up. For drop seizures, which fling patients to the floor, half responded by six months and 61.5 percent by the end. Seizure-free days more than doubled, from 5.7 to 12.5 per month, while hospital visits and injuries from seizures fell.
Catalog record
| CREATOR | Pyae Aung, Debbie Miller, Emily Sewell, Laura Mantoan Ritter, Evangelia Theochari, Ioannis Stavropoulos, Robert Delamont, Mark P. Richardson, Joel S. Winston, Lina Nashef |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |